Literature DB >> 19058314

Effects of recombinant human growth hormone on enterocutaneous fistula patients.

Guo-Sheng Gu1, Jian-An Ren, Ning Li, Jie-Shou Li.   

Abstract

AIM: To explore the effects of recombinant human growth hormone (rhGH) on intestinal mucosal epithelial cell proliferation and nutritional status in patients with enterocutaneous fistula.
METHODS: Eight patients with enterocutaneous fistulas received recombinant human growth hormone (10 microg/d) for 7 d. Image analysis and immunohistochemical techniques were used to analyse the expression of proliferating cell nuclear antigen (PCNA) in intestinal mucosal epithelial cells in biopsy samples from the patients who had undergone an endoscopic biopsy through the fistula at day 0, 4 and 7. Body weights, nitrogen excretion, serum levels of total proteins, albumin, prealbumin, transferrin and fibronectin were measured at day 0, 4 and 7.
RESULTS: Significant improvements occurred in the expression of PCNA in the intestinal mucosal epithelial cells at day 4 and 7 compared to day 0 (24.93 +/- 3.41%, 30.46 +/- 5.24% vs 12.92 +/- 4.20%, P < 0.01). These changes were accompanied by the significant improvement of villus height (500.54 +/- 53.79 microm, 459.03 +/- 88.98 microm vs 210.94 +/- 49.16 microm, P < 0.01), serum levels of total proteins (70.52 +/- 5.13 g/L, 74.89 +/- 5.16 g/L vs 63.51 +/- 2.47 g/L, P < 0.01), albumin (39.44 +/- 1.18 g/L, 42.39 +/- 1.68 g/L vs 35.74 +/- 1.75 g/L, P < 0.01) and fibronectin (236.3 +/- 16.5 mg/L, 275.8 +/- 16.9 mg/L vs 172.5 +/- 21.4 mg/L, P < 0.01) at day 4 and 7, and prealbumin (286.38 +/- 65.61 mg/L vs 180.88 +/- 48.28 mg/L, P < 0.05), transferrin (2.61 +/- 0.12 g/L vs 2.41 +/- 0.14 g/L, P < 0.05) at day 7. Nitrogen excretion was significantly decreased at day 7 (3.40 +/- 1.65 g/d vs 7.25 +/- 3.92 g/d, P < 0.05). No change was observed in the body weight.
CONCLUSION: Recombinant human growth hormone could promote intestinal mucosal epithelial cell proliferation and protein synthesis in patients with enterocutaneous fistula.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19058314      PMCID: PMC2773883          DOI: 10.3748/wjg.14.6858

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Sequential changes of body composition in patients with enterocutaneous fistula during the 10 days after admission.

Authors:  Xin-Bo Wang; Jian-An Ren; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

2.  Effects of growth hormone (rhGH) and glutamine supplemented parenteral nutrition on intestinal adaptation in short bowel rats.

Authors:  Y Gu; Z H Wu; J X Xie; D Y Jin; H C Zhuo
Journal:  Clin Nutr       Date:  2001-04       Impact factor: 7.324

3.  Effects of short-term growth hormone therapy in rats undergoing 75% small intestinal resection.

Authors:  D I Shulman; C S Hu; G Duckett; M Lavallee-Grey
Journal:  J Pediatr Gastroenterol Nutr       Date:  1992-01       Impact factor: 2.839

4.  The trophic action of growth hormone, insulin-like growth factor-I, and insulin on human duodenal mucosa cultured in vitro.

Authors:  E E Wheeler; D N Challacombe
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

5.  Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study.

Authors:  J Szkudlarek; P B Jeppesen; P B Mortensen
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

6.  Growth hormone and glutamine do not stimulate intestinal adaptation following massive small bowel resection in the rat.

Authors:  J A Vanderhoof; K A Kollman; S Griffin; T E Adrian
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-09       Impact factor: 2.839

7.  Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome.

Authors:  T A Byrne; T B Morrissey; T V Nattakom; T R Ziegler; D W Wilmore
Journal:  JPEN J Parenter Enteral Nutr       Date:  1995 Jul-Aug       Impact factor: 4.016

8.  Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study.

Authors:  David Seguy; Kouroche Vahedi; Nathalie Kapel; Jean-Claude Souberbielle; Bernard Messing
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

9.  A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet.

Authors:  T A Byrne; R L Persinger; L S Young; T R Ziegler; D W Wilmore
Journal:  Ann Surg       Date:  1995-09       Impact factor: 12.969

10.  Refeeding syndrome in patients with gastrointestinal fistula.

Authors:  Chao-Gang Fan; Jian-An Ren; Xin-Bo Wang; Jie-Shou Li
Journal:  Nutrition       Date:  2004-04       Impact factor: 4.008

View more
  2 in total

1.  Effectiveness of Recombinant Human Growth Hormone for Pharyngocutaneous Fistula Closure.

Authors:  Nurten Kucuk; Murat Sari; Ahmet Midi; Ali Cemal Yumusakhuylu; Ozan Findik; Adem Binnetoglu
Journal:  Clin Exp Otorhinolaryngol       Date:  2015-11-10       Impact factor: 3.372

2.  Growth hormone receptor expression in human primary gastric adenocarcinoma.

Authors:  Xiaodong Yang; Ping Huang; Feng Wang; Zekuan Xu; Xiaonin Wang
Journal:  J Biomed Res       Date:  2012-09-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.